ESMO-Magnitude of Clinical Benefit Scale

MCBS Banner 1180x184

The ESMO-MCBS is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies at the time of approval.

The below filter has been created to provide a centralised location of cancer medicines that have been scored using ESMO-MCBS v1.1 and published by ESMO.

ESMO-MCBS grading

Curative setting grading  - A (major benefit), B (important benefit), C (minor benefit):

  • Form 1   - For new approaches to adjuvant therapy or new potentially curative therapies

Non-curative setting grading - 5 and 4 (substantial benefit), 3 (moderate benefit), 2 and 1 (negligible benefit):

  • Form 2a   - For therapies that are not likely to be curative with primary endpoint of OS 
  • Form 2b   - For therapies that are not likely to be curative with primary endpoint PFS 
  • Form 2c   - For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies 
  • Form 3     - For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR 

For full information please click here

The ESMO-MCBS Score Card

The ESMO-MCBS Score Card allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

Tested Agent Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Tumour Stage Score Ref. Score card
Trastuzumab Chemotherapy Adjuvant or neo-adjuvant HER2 positive tumours Breast Cancer Breast Cancer HER2+ Early
A
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel (Randomised phase II study) Neo-adjuvant HER2 overexpressed invasive ductal breast Breast Cancer Breast Cancer HER2+ Early
C
T-DM1 Lapatinib + capecitabine 2nd line metastatic after trastuzumab failure (extensive crossover) Breast Cancer Breast Cancer HER2+ Metastatic
4
Pertuzumab Trastuzumab + docetaxel Trastuzumab + docetaxel + placebo 1st line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Trastuzumab Lapatinib Lapatinib 3rd line metastatic Breast Cancer Breast Cancer HER2+ Metastatic
4
Palbociclib Fulvestrant Fulvestrant + placebo 2nd line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
4
Palbociclib Letrozole Letrozole + placebo 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Palbociclib Letrozole Letrozole (Randomised phase II study) 1st line metastatic HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Ribociclib Letrozole Letrozole + placebo 1st line metastatic post-menopause HR+ HER2- Breast Cancer Breast Cancer HR+ HER2- Metastatic
3
Lapatinib Capecitabine Capecitabine 2nd line metastatic after trastuzumab failure Breast Cancer Breast Cancer HER2+ Metastatic
3

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings